Pacific Biosciences Of California (PACB) Total Liabilities (2010 - 2026)

Pacific Biosciences Of California's Total Liabilities history runs 17 years deep, the most recent figure standing at $780.0 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 1.41% year-over-year to $780.0 million; the TTM figure through Mar 2026 stood at $780.0 million (up 1.41% YoY), while the FY2025 annual figure was $778.7 million, up 3.3% from the prior year.
• Total Liabilities was $780.0 million for Q1 2026 at Pacific Biosciences Of California, roughly flat from $778.7 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $1.2 billion in Q2 2023 to a low of $753.9 million in Q4 2024.
• Historically, Total Liabilities has averaged $1.0 billion across 5 years, with a median of $1.0 billion in 2024.
• The sharpest annual moves came in 2022 and 2024: Total Liabilities advanced 23.63% in 2022, then declined 27.84% in 2024.
• A 5-year view of Total Liabilities shows it stood at $1.2 billion in 2022, then decreased by 13.24% to $1.0 billion in 2023, then slipped by 27.84% to $753.9 million in 2024, then advanced by 3.3% to $778.7 million in 2025, then rose by 0.16% to $780.0 million in 2026.
• The last three Total Liabilities figures came in at $780.0 million (Q1 2026), $778.7 million (Q4 2025), and $767.1 million (Q3 2025), per Business Quant data.